Table 1.
Proportion listed and median time-to-listing for all drug indications that received a CDR or pCODR listing recommendation between 1 September 2007 and 31 August 2013, before and after the establishment of the pCPA
| Number (%) of drug indications listed |
Median time-to-listing†, calendar days |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre-pCPA era‡ | pCPA era§ |
p Value¶ |
Pre-pCPA era‡ | pCPA era§ |
p Value** |
|||||
| Jurisdiction | All (n=79) | All (n=91) | pCPA negotiation subgroup (n=31) | Pre-pCPA era vs pCPA era | Pre-pCPA era vs pCPA negotiation subgroup | All | All | pCPA negotiation subgroup | Pre-pCPA era vs pCPA era | Pre-pCPA era vs pCPA negotiation subgroup |
| British Columbia | 37 (47%) | 51 (56%) | 24 (77%) | 0.28 | 0.01* | 267 | 268 | 275 | 0.34 | 0.67 |
| Alberta | 36 (46%) | 37 (41%) | 18 (58%) | 0.54 | 0.29 | 170 | 131 | 189 | 0.03* | 0.85 |
| Saskatchewan | 41 (52%) | 54 (59%) | 24 (77%) | 0.36 | 0.02* | 140 | 138 | 139 | 0.35 | 0.76 |
| Manitoba | 31 (39%) | 45 (49%) | 21 (68%) | 0.22 | 0.01* | 701 | 341 | 390 | <0.001* | 0.001* |
| Ontario | 47 (59%) | 54 (59%) | 21 (68%) | 1.00 | 0.52 | 447 | 223 | 246 | 0.001* | 0.01* |
| New Brunswick | 41 (52%) | 46 (51%) | 19 (61%) | 0.88 | 0.40 | 161 | 249 | 324 | <0.001* | 0.002* |
| Nova Scotia | 33 (42%) | 38 (42%) | 14 (45%) | 1.00 | 0.83 | 155 | 197 | 237 | 0.30 | 0.02* |
| Prince Edward Island | 29 (37%) | 33 (36%) | 12 (39%) | 1.00 | 1.00 | 719 | 457 | 383 | 0.07 | 0.06 |
| Newfoundland and Labrador | 28 (35%) | 38 (42%) | 19 (61%) | 0.43 | 0.02* | 159 | 247 | 324 | 0.94 | 0.45 |
A drug indication was considered ‘listed’ if it had a full or restricted listing status (refer to the Methods section for further details) on the formulary of a provincial drug plan or cancer agency as of 30 April 2014; the pCPA negotiation subgroup refers to drug indications that had completed joint pricing negotiations with the pCPA as of 30 April 2014.
*p<0.05.
†Excludes drug listings in any jurisdiction that occurred before a CDR or pCODR listing recommendation was issued (20 in total; 9 in British Columbia, 2 in Alberta, 2 in Saskatchewan, 1 in Manitoba, 2 in Ontario, none in New Brunswick, 1 in Nova Scotia, 1 in Prince Edward Island and 2 in Newfoundland and Labrador).
‡Refers to drug indications that received a listing recommendation between 1 September 2007 and 31 August 2010.
§Refers to drug indications that received a listing recommendation between 1 September 2010 and 31 August 2013. Two drug-indications still under active pCPA negotiations as of 30 April 2014 were excluded.
¶p values obtained from Fisher’s exact test.
**p Values obtained from the Mann-Whitney U test.
CDR, Common Drug Review; pCODR, pan-Canadian Oncology Drug Review; pCPA, pan-Canadian Pricing Alliance.